Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 278

    1.

    Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.

    Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H.

    Breast Cancer Res. 2008;10(1):R17. Epub 2008 Feb 14.

    PMID:
    18275599
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.

    Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H.

    Breast Cancer Res. 2005;7(1):R93-100. Epub 2004 Nov 19.

    PMID:
    15642173
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

    Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

    Clin Cancer Res. 2008 Apr 1;14(7):1976-83.

    PMID:
    18381935
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.

    Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, Losa M, Manoukian S, Peissel B, Pierotti MA, Pilotti S, Radice P.

    Mod Pathol. 2008 Oct;21(10):1262-70. Epub 2008 Mar 7.

    PMID:
    18327210
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.

    Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H.

    Breast Cancer Res. 2005;7(4):R465-9. Epub 2005 Apr 21.

    PMID:
    15987451
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

    Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.

    Clin Cancer Res. 2004 Mar 15;10(6):2029-34.

    PMID:
    15041722
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

    Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL; kConFab Investigators.

    Genes Chromosomes Cancer. 2004 Mar;39(3):236-48.

    PMID:
    14732925
    [PubMed - indexed for MEDLINE]
    8.

    Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.

    Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.

    Clin Cancer Res. 2005 Jun 1;11(11):4003-11.

    PMID:
    15930334
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

    Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J.

    Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14.

    PMID:
    14506147
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

    Honrado E, Benítez J, Palacios J.

    Mod Pathol. 2005 Oct;18(10):1305-20. Review.

    PMID:
    15933754
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

    Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J.

    J Clin Pathol. 2007 Sep;60(9):1006-12. Epub 2006 Nov 14.

    PMID:
    17105822
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

    Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

    Br J Cancer. 2009 Jan 27;100(2):421-5. Epub 2008 Dec 16.

    PMID:
    19088722
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

    Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.

    Cancer Res. 2003 Jan 15;63(2):342-7.

    PMID:
    12543786
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    The molecular pathology of hereditary breast cancer.

    Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J.

    Pathobiology. 2008;75(2):85-94. Epub 2008 Jun 10. Review.

    PMID:
    18544963
    [PubMed - indexed for MEDLINE]
    16.

    Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.

    Miolo G, Canzonieri V, De Giacomi C, Puppa LD, Dolcetti R, Lombardi D, Perin T, Scalone S, Veronesi A, Viel A.

    BMC Cancer. 2009 Oct 10;9:360.

    PMID:
    19818148
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

    Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL.

    J Clin Oncol. 2001 Apr 15;19(8):2247-53.

    PMID:
    11304778
    [PubMed - indexed for MEDLINE]
    18.

    Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

    Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.

    J Clin Oncol. 2009 Dec 10;27(35):5887-92. Epub 2009 Oct 26.

    PMID:
    19858402
    [PubMed - indexed for MEDLINE]
    19.

    Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

    Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

    Am J Surg Pathol. 2009 Jul;33(7):1093-7.

    PMID:
    19390427
    [PubMed - indexed for MEDLINE]
    20.

    Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.

    Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K.

    BMC Cancer. 2008 May 20;8:140.

    PMID:
    18489799
    [PubMed - indexed for MEDLINE]
    Free PMC Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk